DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 06/18/2019 --Onychomycosis Market Insights, Epidemiology and Market Forecast-2028

1. Onychomycosis occurs in 10% of the general population but is more common in older adults.
2. Onychomycosis is more common in smokers and in those who use occlusive footwear and shared bathing facilities.
3. Men are affected more frequently possibly due to more frequent nail damage from sports and leisure activities.

DelveInsight launched a new report on Onychomycosis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Onychomycosis market report covers a descriptive overview and comprehensive insight of the Onychomycosis epidemiology and Onychomycosis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Onychomycosis market report provides insights on the current and emerging therapies.
3. Onychomycosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Onychomycosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Onychomycosis market.

Request for sample pages

"Onychomycosis in childhood is rare and affects approximately 0.5% to 2.6% of all children."
In the Onychomycosis treatment, the desired endpoints are a mycological, clinical, and complete cure. Onychomycosis treatment can be either topical, systemic, or a combination of both. Oral/Systemic antifungals are used for onychomycosis treatment that includes griseofulvin, azoles including ketoconazole, itraconazole and fluconazole, and allylamine terbinafine.
In an attempt to improve the cure rate and reduce relapse, the use of combination therapy has become necessary. The combination of oral and topical drugs may allow a reduction in oral dosing resulting in increased patient tolerance and compliance while improving efficacy and reducing relapse. Itraconazole and amorolfine lacquer; oral terbinafine and amorolfine lacquer were shown to be effective.
Increase in research and development activities, the rise in demand for effective Onychomycosis therapies among patients, an upsurge in Onychomycosis prevalence is projected to fuel the growth of the Onychomycosis market during the forecast period.

The launch of the emerging therapies is expected to significantly impact the Onychomycosis treatment scenario in the upcoming years:-
Drugs covered
1. MOB-015
2. P3058
3. Novexatin
4. BB2603
And many others

The key players in Onychomycosis market are:
1. Almirall
2. NovaBiotics
3. Blueberry Therapeutics
4. Moberg Pharma
And many others

Table of contents

1. Report Introduction
2. Onychomycosis Market Overview at a Glance
3. Onychomycosis Disease Background and Overview
4. Onychomycosis Epidemiology and Patient Population (7MM)
5. Onychomycosis Country- Wise Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Onychomycosis Treatment & Medical Practices
7. Onychomycosis Marketed Therapies
7.1. Kerydin (tavaborole): Anacor Pharmaceuticals
7.2. Jublia (efinaconazole): Valeant Pharmaceuticals
8. Onychomycosis Emerging Therapies
8.1. Key Cross Competition
8.2. MOB-015: Moberg Pharma
8.3. P3058: Almirall
8.4. BB2603: Blueberry Therapeutics
8.5. Novexatin: NovaBiotics
9. Onychomycosis Market Size
10. Onychomycosis Country-Wise Market Analysis 7MM
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
13. Onychomycosis Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight